RhoGAM shots play a crucial role in mitigating the risk of Rh sensitization for Rh-negative expectant mothers. In cases where the maternal blood type lacks the Rh factor (Rh-negative) while the fetus possesses it (Rh-positive), the absence of RhoGAM intervention could lead to the generation of alloimmunization antibodies within the maternal immune system. These antibodies pose a considerable threat to subsequent pregnancies. Administered typically at approximately 28 weeks gestation and postpartum, RhoGAM injections effectively suppress this immune response, thereby ensuring the immunological well-being of both the mother and her fetus.
